Makemation: a Nollywood movie that shows AI in action in Africa 
Elliott Investment Management Takes Multibillion-Dollar Stake in Synopsys 
Palantir's Maven AI Earns Pentagon "Program of Record" Status, Reshaping Military AI Strategy 
Goldman Sachs Sees Value in European Real Estate Stocks Despite Sharp Selloff 
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI 
WTO Ministerial Collapse Leaves Global Digital Trade Rules in Limbo 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Oil Prices Surge to Record Monthly Highs as Middle East War Rattles Global Markets 
Japan Business Sentiment Rises as Iran War Fuels Inflation Fears, BOJ Rate Hike Looms 
Aluminum Prices Surge Toward Four-Year Highs After Gulf Smelter Strikes 
Trump White House Unveils National AI Policy Framework for Congress 
Australia Bans Card Payment Surcharges Starting October 2025 
California's AI Executive Order Pushes Responsible Tech Use in State Contracts 
Bessent: Global Oil Market Well Supplied as U.S. Eyes Hormuz Navigation Control 
U.S. Trade Rep Dismisses WTO's Future Role After Failed Cameroon Summit 
Asian Currencies Hold Steady Amid U.S.-Israel-Iran Tensions and BOJ Signals 
South Korea's $17.3 Billion Emergency Budget Targets Oil Price Surge 
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
